Eugia Pharma receives USFDA Approval for Bortezomib for Injection

Aurobindo Pharma Limited's wholly owned subsidiary company, Eugia Pharma Specialties Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bortezomib for injection, 3.5 mg. Bortezomib for Injection, 3.5 mg/vial (Single-Dose Vial) to be bioequivalent and therapeutically equivalent to the Velcade for Injection 3.5 mg/vial, of Takeda Pharmaceuticals U.S.A. Inc. The product is being launched immediately. The approved product has a market size of US$ 1172 million for the twelve months ending March 2022, according to IQVIA.

This is the 136th ANDA (including 7 tentative approvals) to be out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Bortezomib for injection is indicated for the treatment of

- Adult patients with multiple myeloma (cancer of plasma cells)
- Also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes)

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 642.35 as compared to the previous close of Rs. 629.65. The total number of shares traded during the day was 102864 in over 4666 trades.

The stock hit an intraday high of Rs. 653.00 and intraday low of 625.00. The net turnover during the day was Rs. 66092747.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EugiaPharma USFDA Approval Bortezomib Injection